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This session highlighted current issues in clinical trials and, in
particular, the importance of designing trials that are appro-
priate to the newer biological agents targeting specific
cellular processes in tumours. Per Lønning described the
different phases of clinical trials from I to III. He highlighted
the importance of conducting extensive pharmacokinetic
analyses during trials and of intensive characterization of
drugs and their effects from the earliest phases of
development. There are many ways in which this can be
achieved, including pharmacodynamic assessments of drug
effect and more complex gene chip assays, which can be
used to predict who will be responders and nonresponders
to particular treatments. Kathy Pritchard grappled with
challenges faced by current trials, including the overbearing
burden of regulation, the high costs of conducting trials in the
host institution and the ‘publish or die’ mentality of academia.
It is increasingly difficult to raise funds for trials, and ‘sexy’
research topics risk being prioritized ahead of the clinically
relevant or those using older technologies. Clinical trial
designs must be relevant to the whole population with the
disease, not just the trial population, and the clinical indica-
tions for new drugs should not be limited by slavish applica-
tion of restrictive trial entry criteria when the results are
applied to the population.
Ian Smith and Mitch Dowsett described a series of trials
conducted at the Royal Marsden Hospital of preoperative
exposure to drugs. Neoadjuvant treatment allows assessment
of drug effects with the primary tumour in situ, but the key
question is whether the observed treatment effect in this
setting translated into improved outcomes in the longer term.
Clinical response appears to correlate poorly with long-term
outcome, but pathological complete response can be used to
identify a group with better prognosis. The problem is that
there are few pathological responses in the majority of neo-
adjuvant studies. Change in Ki67 staining after short-term
exposure to drug does, however, appear to correlate better
with longer-term outcome than does clinical response, and
this might be a useful surrogate marker. Professor Dowsett
explained how Ki67 could better identify biological changes
than tumour shrinkage because it takes into account the rate
of proliferation at baseline. Thus, a rapidly growing tumour
that appeared to respond only poorly clinically might actually
have been dramatically ‘slowed down’, based on assessment
of Ki67. Short-term exposure to drug before a traditional
primary surgical approach may give useful biological
information, and this approach is being tested in the POETIC
(Pre-Operative Endocrine Therapy Individualised Care) study.
Carlos Arteaga described how understanding of the
mammalian target of rapamycin (mTOR) pathway in brain
tumours could lead to prediction of outcome and the
importance of translational, bench-to-bedside research in
elucidating the interactions of drugs with complex growth
signalling pathways.
In conclusion, in this session the importance of careful trial
design of relevance to patients was emphasized. There
should be extensive study of all aspects of drug action and
metabolism in nonrandomized studies, so that when we
embark on phase III trials including thousands of patients we
know as much as possible about the effects of the drug. We
are, as yet, some way off eliminating the need for these
massive trials, because surrogate markers of outcome do not
allow us to identify with sufficient precision those who will or
will not benefit from an intervention. We must also be careful
that the few per cent of cancer patients who do enter trials
are relevant to the many who do not. One of the greatest
challenges we face is applying the findings from the small
subset of trial participants to all of the individuals in the
population of breast cancer patients.
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